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The past decade has witnessed fluorescently tagged drug molecules gaining significant attraction in their use as
pharmacological tools with which to visualize and interrogate receptor targets at the single-cell level. Additionally, one can
generate detailed pharmacological information, such as affinity measurements, down to almost single-molecule detection
limits. The now accepted utilization of fluorescence-based readouts in high-throughput/high-content screening provides
further evidence that fluorescent molecules offer a safer and more adaptable substitute to radioligands in molecular
pharmacology and drug discovery. One such drug-target family that has received considerable attention are the GPCRs; this
review therefore summarizes the most recent developments in the area of fluorescent ligand design for this important drug
target. We assess recently reported fluorescent conjugates by adopting a receptor-family-based approach, highlighting some
of the strengths and weaknesses of the individual molecules and their subsequent use. This review adds further strength to
the arguments that fluorescent ligand design and synthesis requires careful planning and execution; providing examples
illustrating that selection of the correct fluorescent dye, linker length/composition and geographic attachment point to the
drug scaffold can all influence the ultimate selectivity and potency of the final conjugate when compared with its unlabelled
precursor. When optimized appropriately, the resultant fluorescent conjugates have been successfully employed in an array of
assay formats, including flow cytometry, fluorescence microscopy, FRET and scanning confocal microscopy. It is clear that
fluorescently labelled GPCR ligands remain a developing and dynamic research arena.
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Introduction
Recent years have witnessed a rapid expansion in the use of
fluorescence-based techniques with which to interrogate bio-
logical processes and receptors of physiological and pharma-
cological importance. There are a number of methods by
which a fluorescent probe can be generated, including
genetic manipulation to label a protein with a fluorophore
(Dedecker et al., 2013), measurement of the inherent fluores-
cence of a compound (Beltran et al., 2011; Burchak et al.,
2011) or by using synthetic chemistry to covalently link a
biologically active compound to a fluorophore of choice,
creating a fluorescent ligand conjugate (Daly and McGrath,
2003). Fluorescent ligands can be designed to interact with
different entities, for example, as reaction-based probes,
which offer a powerful technique for detecting and studying
small molecules and/or metal ions of interest in living
systems (Chan et al., 2012). However, the most prevalent use
of fluorescent ligands has been the study of protein–protein
interactions (Kale et al., 2012) or ligand–receptor interactions
(Leopoldo et al., 2009) in biological systems.
One of the most important human receptor families, from
a drug discovery and development perspective, is the GPCRs
(Alexander et al., 2013). GPCRs are 7-transmembrane span-
ning receptors, which account for nearly 4% of the protein-
encoding human genome (Bjarnadóttir et al., 2006) and are
the target of approximately 30% of all marketed drugs
(Overington et al., 2006). GPCRs have been classified into five
different classes (http://www.gpcr.org/7tm/proteinfamily), of
which Class A is the largest and generally regarded as the
most understood. GPCRs are signalling powerhouses and can
regulate various intracellular biological cascades via the
binding of extracellular endogenous ligands, such as pep-
tides, hormones and neurotransmitters. There is significant
interest surrounding the development of fluorescent ligands
with which to study GPCRs, and research reports of fluores-
cent GPCR ligands have been previously reviewed (Middleton
and Kellam, 2005; Kuder and Kiec´-Kononowicz, 2008; Böhme
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and Beck-Sickinger, 2009). This article summarizes the small-
molecule (non-peptide) fluorescent conjugates for Class A
GPCRs that have been reported subsequent to these afore-
mentioned reviews.
Fluorescent ligands are powerful tools to study GPCRs as
they can be employed in many varied experiments to reveal
insight into receptor structure and function in native, live
cells (Briddon et al., 2011). High-affinity fluorescent antago-
nists can be used to label the target GPCR, and fluorescently
tagged agonists can provide a means to monitor dynamic
processes such as receptor internalization and trafficking (cf.
examples within this review). A fluorescent ligand can be
used as the competing probe in a competition-based binding
assay (Cottet et al., 2011; Sexton et al., 2011; Stoddart et al.,
2012) instead of a radiolabelled ligand, thereby avoiding the
inherent safety risks, legal issues and disposal costs associated
with the latter. In addition to measuring the direct displace-
ment of a competing fluorescent ligand from a GPCR orthos-
teric site, fluorescent ligands have enormous potential for
revealing elaborate and intricate details about receptor oli-
gomerization through the use of FRET and BRET assays
(Albizu et al., 2010; Cottet et al., 2011; 2012). Kinetic meas-
urements of the fluorescent ligand–receptor interaction can
reveal insight into receptor allosterism (Hill et al., 2014, this
issue) and receptor dimerization (May et al., 2011), while
ligand–receptor diffusion times measured using techniques
such as fluorescence correlation spectroscopy (FCS) can be
used to distinguish different receptor complexes (Briddon
and Hill, 2007; Jakobs et al., 2012). This brief precis highlights
just some of the possible applications of fluorescent ligands
in what is becoming a rapidly expanding field.
Fluorescent ligands for GPCRs
The design of a small-molecule-based fluorescent probe
begins with selecting an amenable parent pharmacophore,
surveying where to append the linker, determining what
linker to use and, lastly, deciding what fluorophore to cova-
lently tether (Jacobson, 2009). The linker position on the
parent ligand must be tolerant to chemical change, which is
often driven by existing structure activity relationship (SAR)
data where available. There is an increasingly diverse range of
commercially available fluorophores, and often the commer-
cial fluorophore can be purchased as the pre-activated
N-hydroxysuccinimidyl (NHS) ester primed for coupling to
an amine on the pharmacophore-linker congener. Properties
to consider when selecting the appropriate fluorophore to
append to a congener include the absorption and emission
profile of the fluorophore, lipophilicity (which can influence
the conjugate’s ability to diffuse across the cell membrane)
and whether the fluorophore is quenched in certain environ-
ments. From a GPCR imaging perspective, the fluorescent
ligand will ideally not enter the cells (unless bound to the
internalized receptor), show very low levels of non-specific
membrane binding, be quenched when not bound to the
receptor and/or cell membrane and, for most applications, be
displaceable using higher concentrations of a known non-
fluorescent ligand that targets the same receptor. Once
assembled, the fluorescent conjugate must be rigorously
pharmacologically characterized, as its profile in terms of
affinity and/or efficacy may be very different from that of
the parent ligand. In the following sections, we review the
small-molecule-based fluorescent conjugates that have been
developed for Class A receptor families since publication of
earlier reviews of this subject area (Middleton and Kellam,
2005; Kuder and Kiec´-Kononowicz, 2008; Böhme and
Beck-Sickinger, 2009).
Adenosine receptor
The use of fluorescent probes for studying the adenosine
receptor has recently been comprehensively reviewed by
Kozma et al. (2013b). The fluorescent ligand toolbox for the
adenosine receptor family is relatively advanced compared
with other Class A GPCRs, with many reports of both antago-
nist and agonist-based probes built around different pharma-
cophores (predominately for the A1- and A3-adenosine
receptor subtypes) by the research groups of Jacobson and
Hill/Kellam (refer to references within Kozma et al., 2013b).
Use of fluorescent antagonists for the adenosine A1- and
A3-receptors is now at a stage where they can be used in place
of radioligand-binding studies for screening purposes. A good
example of this is a recent report from our laboratories of
high-content screening of a fragment library to identify new
synthetic scaffolds for the human A1- and A3-adenosine recep-
tor family subtypes (Stoddart et al., 2012). Since the review by
Kozma and colleagues, there has been one additional account
comparing the pharmacology and imaging properties of three
new agonist-based fluorescent adenosine A3-receptor probes
(Kozma et al., 2013a) to five alternatives that had been pre-
viously reported (Tosh et al., 2009). The new compounds
included an IR dye 700 DX conjugate (1) linked through the
C2 position of the adenine nucleoside ring, and two
N6-linked Alexa Fluor 488 probes (2) and (3) synthesized by
click-coupling between an azide and alkyne. The three novel
conjugates unfortunately displayed a weaker adenosine
A3-receptor potency when compared with the originally
reported fluorescent ligands, and therefore, the authors pro-
ceeded with imaging studies using the previously reported
Cy5-containing MRS5218 (Tosh et al., 2009) as their first-
choice fluorescent probe to visualize and study both the
human and the mouse A3-receptor.
Adrenoceptor
Martikkala et al. (2009) constructed three europium(III)-
labelled probes for the β2-adrenoceptor by coupling amino
pindolol derivatives containing different linker lengths to
isothiocyanate-activated europium chelates [the chemical
moiety(s) of these chelates were not disclosed]. The com-
pounds with the shortest (4) and longest (5) linker-length
were employed in a competitive time-resolved fluorescence
emission-binding assay using the beta-blocker propranolol as
the model drug. IC50 values of 60 and 37 nM for the human
β2-adrenoceptor were obtained for propranolol using (4) and
(5), respectively, compared to a value of 33 nM calculated
from a [3H]dihydroalprenolol radioligand displacement assay.
It was interesting to note that an intermediate linker-length
europium conjugate (5 minus one of the heptanamide units)
could not displace propranolol from the β2-adrenoceptor.
This is intriguing, as one might expect the structure–activity
relationship trend of linker length to be consistent, up to a
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point, in any one direction. This demonstrates that a fluores-
cent conjugate can possess a complex, unique and often
unpredictable pharmacological profile compared with the
parent pharmacophore.
In a comprehensive study from our laboratories, a series
of red-fluorescent β-adrenoceptor ligands were synthesized
based on three different orthosteric β-antagonist head groups;
namely propranolol, alprenolol and pindolol (Baker et al.,
2011). Using alkyl- or polyether-based linker extensions,
the resultant propranolol (6) and alprenolol-based (7) fluo-
rescent β-blockers displayed high affinity for the human
β2-adrenoceptor. This study provided a further example of
how subtle changes in the structural nature of the linker can
exert a significant impact on the final conjugate’s pharma-
cology. The 8-carbon linker analogue of 6, where the ‘PEG-
like’ linker was replaced with a hydrocarbon chain, showed
a 10-fold lower affinity for the β2-adrenoceptor compared
to 6. In contrast, when the linker of 6 was replaced with a
shorter 4-carbon linker, the conjugate’s affinity for the
β2-adrenoceptor was comparable to 6. Conjugate 6 was used
to visualize ligand–receptor binding in CHO-β2 cells express-
ing the human form of the β2-adrenoceptor using confocal
microscopy, and displayed clear labelling of the membrane-
bound receptors at 3 nM. This specific binding could be
attenuated by incubation with various concentrations
(1–100 nM) of the β2-selective antagonist ICI 118551. In this
study, it was also of interest to note that the pindolol-based
fluorescent conjugates showed significant loss of affinity
when compared with the native drug molecule. Even with
three orthosteric ligands acting upon the equivalent receptor-
binding pocket, one cannot therefore assume that installa-
tion of a fluorophore onto the analogous position of a
congener will afford similar pharmacological outcomes with
regard to the final conjugate.
Morishima et al. (2010) developed a high-affinity fluores-
cent probe (8) selective for the α1A-adrenoceptor and α1L-
adrenoceptor (thought to be an α1A-adrenoceptor phenotype)
over the α1B-adrenoceptor and α1D-adrenoceptor subtypes.
The α1A-adrenoceptor subtype selective antagonist silodosin,
which is used to treat bladder outlet obstruction, was labelled
with an Alexa Fluor 488 fluorophore. The authors did not
disclose which isomer of the fluorophore was used, and there-
fore the Alexa Fluor 488 mixture of 5′ and 6′ isomers has been
depicted in Table 1. While fluorescent probe 8 displayed a
10-fold reduction in binding affinity across the human
adrenoceptor receptor subtypes as compared with silodosin,
it retained an α1A-adrenoceptor selectivity profile (100- and
15-fold selective over α1B-adrenoceptor and α1D-adrenoceptor
respectively). Fluorescent confocal microscopy demonstrated
that 8 localized to the membrane of CHO cells overexpressing
the α1A-adrenoceptor, and this binding could be significantly
reduced using the high-affinity selective antagonist prazosin.
Building on this promising result, 8 was used to visualize the
α1L-adrenoceptor, an α1A-adrenoceptor phenotype, localized
to the muscle layer of the human prostate.
Angiotensin receptor
A fluorescent angiotensin II AT1 receptor (AT1R) ligand has
been reported, derived from a sartan-based pharmacophore
(Giarrusso et al., 2012). In place of the thiophene carboxylate
moiety of the antagonist milfasartan, Giarrusso et al. (2012)
instead installed various polyaromatic hydrocarbons or a cou-
marin fluorophore (e.g. 9) by reacting an alkyl halide with
the pyrimidinone pharmacophore core. The authors remark
that polyaromatic conjugates, such as those containing a
naphthalene moiety, were clearly unsuitable for in vivo use;
therefore, coumarin-conjugate 9 was further evaluated as a
potential visual AT1R probe. Functional analysis using CHO
cells expressing the rat AT1aR revealed that 9 was an antago-
nist of the AT1R, with an estimated pKb value similar to the
native drug. Although the authors state that 9 was a selective
ligand for the AT1R, no pharmacological data were provided
for other angiotensin receptors to confirm this statement.
The ability of 9 to label the AT1R was evaluated, but unfor-
tunately, significant accumulation of fluorescence in the cell
cytoplasm was observed even with non-AT1R transfected
CHO cells. Development of less lipophilic fluorescent ligands,
to eliminate this intracellular localization, is an ongoing work
in the authors’ laboratory.
Cannabinoid receptor
In a recent report by Sexton et al. (2011), two newly designed
CB2 cannabinoid receptor (CB2R) fluorescent probes (10) and
(11) were compared with the previously reported fluorescent
antagonist NIRmbc94 (12) (Bai et al., 2008). The purpose of
these new conjugates was to examine the influence of linker
location around the core of the antagonist. The parent phar-
macophore, CB2R selective antagonist SR144528, lacked an
intrinsic biological handle such as an amine or carboxylic
acid. Therefore, a 6-(aminohexyl)aminomethyl tether was
incorporated in additional positions to that previously
reported for 12, and then coupled to the near-infrared IRDye
800CW-NHS ester. The two new compounds did not demon-
strate measurable binding to mouse delayed brain tumour
cells that heterologously express the mouse CB2R; conse-
quently, the fluorescent conjugate of choice remained the
previously reported NIRmbc94 (12). This study reinforces the
importance of identifying a tolerant location on the pharma-
cophore for linker attachment and, as anticipated, demon-
strates that different linker positions can have dramatic
effects on final conjugate pharmacology. NIRmbc94 (12) was
subsequently used as the competing probe in a competition-
binding assay (Sexton et al., 2011), and this methodology was
further elaborated by screening a small compound library to
reliably identify known CB2R binders. The authors then went
on to demonstrate that NIRmcb94 can identify endogenously
expressed CB2R in a mouse microglia cell line, BV-2.
Instead of the more common approach of conjugating a
known, discrete orthosteric ligand via a linker to a fluoro-
phore, the fluorescent moiety can instead be designed as
part of the primary ‘pharmacophore’ scaffold with rational
receptor–ligand interactions in mind. This approach was
employed by Petrov et al. (2011), who constructed isatin
acylhydrazone-based antagonist 13 that demonstrated selec-
tivity for the human CB2R (over human CB1R). A methoxyi-
satin derivative was linked to a 7-nitro-2,1,3-benzoxadiazole
(NBD) fluorophore to afford 13, which, although displaying
slightly reduced affinity to the comparable non-fluorescent
compound fragment, retained the desired CB2R selectivity
profile. Using fluorescent confocal microscopy, the associa-
tion of 13 with T-cells could be visualized, and this interac-
tion could be blocked using a non-fluorescent selective CB2R
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Table 1
Recently reported small-molecule fluorescent conjugates with application to GPCRs
Compound
No.
Target
receptor Structure Reference
1 Adenosine
receptor
Kozma et al.
(2013a)
2
3
4 β2-Adrenoceptor Martikkala
et al. (2009)
5
6 β2-Adrenoceptor Baker et al.
(2011)
7
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Table 1
Continued
Compound
No.
Target
receptor Structure Reference
8 α1A- and
α1L-adrenoceptor
Morishima
et al. (2010)
9 Angiotensin AT1
receptor
Giarrusso et al.
(2012)
10–12 CB2 cannabinoid
receptor
N
N
R1
O
N H
R3
C l
R2
O
N
N
SO3H
SO3H
SO3H
SO3
O
N
H 5
N
H 6
= Fl
10: R1 = Fl, R2 & R3 = H
11: R2 = Fl, R1 & R3 = H
12: R3 = Fl, R1 & R2 = H
Sexton et al.
(2011)
13 CB2 cannabinoid
receptor
Petrov et al.
(2011)
14 Histamine H1
receptor
Rose et al.
(2012)
15 Histamine H3
receptor
Kuder et al.
(2009)
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Table 1
Continued
Compound
No.
Target
receptor Structure Reference
16 Histamine H3
receptor
Tomasch et al.
(2012c)
17
18
19 Histamine H3
receptor
Tomasch et al.
(2012b)
20 Serotonin1A
receptor
(5-HT1A)
Lacivita et al.
(2010)
21 Serotonin1A
receptor
(5-HT1A)
Alonso et al.
(2010)
22 Muscarinic M3
receptor
Jones et al.
(2008)
23 Muscarinic M1
receptor
Hern et al.
(2010)
24
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Table 1
Continued
Compound
No.
Target
receptor Structure Reference
25 Muscarinic M1
receptor
Daval et al.
(2012)
26 Prostanoid EP3
receptor
Tomasch et al.
(2012a)
27 Vasopressin V2
receptor
Loison et al.
(2012)
28
29
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antagonist. Using flow cytometric analysis, the authors
also revealed that 13 is associated with the CB2R in B
lymphocytes.
Histamine receptor
A high-affinity fluorescent antagonist (14) for the human
histamine H1 receptor (H1R) has been reported by Rose et al.
(2012) consisting of the high-affinity and H1R-selective
antagonist mepyramine linked to the BODIPY 630/650 fluo-
rophore. Although fluorescent ligand 14 was purchased from
a commercial supplier and not synthesized by the authors in
this publication, it represents the first disclosure of the
chemical structure of 14. Conjugate 14 displayed comparable
affinity for the H1R compared with the parent pharmacoph-
Table 1
Continued
Compound
No.
Target
receptor Structure Reference
30 Nuclear
oestrogen
receptor
Céspedes-
Guirao et al.
(2011)
31 Nuclear
oestrogen
receptor
H O
O H
H
H
H
N
N
RO2C
(CH2)4SO3
O3S
R  =
O
H O
O H
O H
H O
H3N
Jose et al.
(2011)
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ore mepyramine. Confocal microscopy revealed specific and
displaceable binding of 14 to the H1R localized to the cell
membrane, and despite significant non-specific intracellular
uptake, this probe proved very useful for studying the recep-
tor in single living cells. The diffusion coefficient of 14-H1R
complexes was quantified using FCS, and these values were
different for CHO-K1 cell lines transiently expressing the H1R
with and without the yellow fluorescent protein receptor tag.
The authors then developed this further, by showing that FCS
experiments using 14 can detect endogenously expressed
H1Rs in HeLa cells.
Kuder et al. (2009) have reported 15 as a selective
H3R fluorescent antagonist, which consists of a
piperidine-containing pharmacophore (related to the
known H3R selective antagonist pitolisant) linked to a
nitrobenzoxadiazole-based fluorophore. The only difference
between 15 and a fluorescent probe previously developed by
Amon et al. (2007) is the presence of a 3-methyl group on the
piperidine ring of 15. Conjugate 15 was twofold less potent
for the human H3R than the previously reported non-
methylated derivative (Amon et al., 2007), and the authors
did not evaluate the selectivity or imaging properties of 15.
In another report of an H3R fluorescent ligand, but with a
goal of making red-shifted probes, Tomasch et al., (2012c)
have tethered selective H3R antagonists, again based on a
piperidine moiety, to substituted chalcones. A series of
pharmacophore–fluorophore combinations containing dif-
ferent linker positions and lengths were synthesized, and all
exhibited nanomolar affinity for the human H3R and selec-
tivity over the H1R (one log unit) and H4R (two log units). The
authors then examined the ability of three conjugates (16–
18) to visualize the H3R in hH3-HEK-293 cells. Confocal
microscopy revealed enrichment of the fluorescent signal to
the cell membrane, and the authors conclude that this was
specific binding to the H3R as when HEK-293 cells that do not
transiently express the H3R were treated with the fluorescent
ligands, no enriched membrane fluorescence was observed.
From the same laboratory, Tomasch et al. (2012b) have
used the same piperidine-based pharmacophore but now
with the boron-dipyrromethene scaffold as the fluorophore
(19). Synthesis of the fluorophore moiety was completed by
reaction with boron trifluoroetherate as the final reaction
in a stepwise synthesis, rather than the more common
convergent approach of coupling a pre-activated (and
often commercially available as the NHS ester) fluorophore
to a complementary pharmacophore/linker. Conjugate 19,
named Bodilisant by the authors, displayed a low nanomolar
affinity for the human H3R that was 10 times more potent
that the previous generation (16–18) of conjugates (Tomasch
et al., 2012c). Again, H3R subtype selectivity was maintained.
Fluorescence microscopy was used to visualize the human
H3R in H3-HEK-293 cells and showed that 19 predominately
localized to the cell membrane. In these experiments, the
authors concluded that fluorescent probe 19 was not inter-
nalized, as it did not overlap with the nuclear stain DAPI.
5-Hydroxytryptamine (serotonin) receptor
Lacivita et al. (2010) designed and synthesized a fluorescent
probe (20) for the serotonin1A receptor (5-HT1AR) in an effort
to improve on previous ligands from the same laboratory that
showed high levels of non-specific binding. A chromenone-
containing fluorophore was synthesized in-house and
coupled to a 1-arylpiperizine-based antagonist, affording a
conjugate with nanomolar affinity for the human 5-HT1AR;
approximately 10-fold less potent than the parent piperizine
pharmacophore. The authors then evaluated the ability of 20
to visualize the 5-HT1AR, and using a high concentration of
20, showed fluorescent labelling of CHO-5-HT1A cells that was
reduced by application of serotonin. Along with the lead
ligand (20), a conjugate containing a near-infrared fluoro-
phore was also synthesized, and despite a similar affinity for
the 5-HT1AR compared to 20, the authors commented that
due to the loss of fluorescent properties as measured in
aqueous buffer, it was not useful as an imaging probe.
However, given the location of the 5-HT1AR, as with all Class
A GPCRs, in the cell membrane, it would be interesting to
study the properties of this ligand when bound to the recep-
tor. It can be advantageous to have a fluorescent probe that is
quenched in an aqueous environment (Baker et al., 2010) but
fluoresces when associated with the receptor in a lipophilic
membrane environment. For example, in competition-
binding assays, this property can eliminate the need for thor-
ough washing steps prior to analysing membrane-localized
fluorescence.
Fluorescent 5-HT1AR probes have also been developed by
Alonso et al. (2010) based on an arylpiperazine agonist pre-
viously reported from the same research group. A series of
compounds were synthesized using the 7a-position of the
bicyclohydantoin moiety to tether a dansyl fluorophore.
Several conjugates showed an affinity for the human 5-HT1AR
that were comparable to the starting arylpiperazine scaffold.
Conjugate 21 was identified as the lead fluorescent ligand
due to a high fluorescent intensity emission value. Fixed
CHO-5-HT1AR cells could be labelled with 21 and this could
be blocked using a reference non-fluorescent ligand. Despite
being based on a known agonist, only radioligand competi-
tion binding assays were carried out to determine the affinity
of 21 for the 5-HT1AR – no information was provided regard-
ing how linkage to the dansyl fluorophore influenced ligand
efficacy. The authors did not comment on localized mem-
brane fluorescence or the potential of the fluorescent conju-
gate (if indeed an agonist) to internalize with the receptor.
However, the timescale for the visualization experiments was
only 10 min pre-incubation followed by a wash, fix and
mount process, which may therefore have precluded this
from occurring.
Muscarinic receptors
A fluorescent antagonist (22) of the muscarinic M3 receptor
(M3R) has been reported by Jones et al. (2008), by linking the
non-subtype selective M3R antagonist tolterodine to the com-
mercially available fluorophore BODIPY 630/650-NHS ester.
Conjugate 22 displayed a threefold loss in affinity for the
human M3R compared with tolterodine, and also approxi-
mately the same fold-loss in affinity across the other human
muscarinic receptor subtypes. The authors did not examine
the use of 22 as an imaging tool, but indicated that this was
an ongoing work in their laboratory.
Hern et al. (2010) have reported 23 as an M1R probe,
synthesized by the reaction of a telenzepine amino congener
to an Alexa Fluor 488 fluorophore. Conjugate 23 had a
nanomolar affinity for the human M1R and very slow
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dissociation kinetics, making it an ideal tool to visualize and
monitor receptor–ligand complexes in living cells. Alongside
the previously reported high-affinity M1R ligand 24 (Harris
et al., 2003), total reflection fluorescence microscopy was
used to track the position of fluorescent ligand–receptor com-
plexes in live CHO cells expressing the human M1R. Informa-
tion about M1R mobility, clustering and, in particular,
dimerization could be obtained by simultaneously using
probes 23 and 24 that have different fluorescence emission
wavelengths.
Daval et al. (2012) synthesized fluorescent M1R ligand 25
by coupling an agonist (based on AC-42) with high func-
tional selectivity for the M1R to the fluorophore lissamine
rhodamine B sulfonyl chloride. The emphasis in this study
was on investigating how the fluorescent conjugate binds to
the M1R, and teasing out possible ‘non-orthosteric’ binding
mode(s) and receptor–ligand interactions. The parent agonist
pharmacophore and conjugate 25 displayed a similar affinity
towards the human M1R receptor, but interestingly, 25 could
no longer elicit a typical agonist-induced calcium response in
a functional assay. Instead, 25 fully reduced the functional
response to a known agonist, thereby classifying 25 as an
antagonist. In a series of very comprehensive and interesting
experiments involving assays with reference allosteric
ligands, receptor truncation, molecular modelling and even
application of 25 itself as a FRET tracer, the authors con-
cluded that binding of 25 to the M1R showed a bitopic
(Valant et al., 2012) nature. This work further demonstrates
the importance of treating the ligand-linker–fluorophore
conjugate as a new chemical entity, which can have subtle or
quite profound pharmacological differences compared with
the starting drug molecule. These differences are often not
captured in a single competition-based affinity assay, and
there is a fascinating road ahead in terms of rationalizing
ligand–receptor interactions of fluorescent conjugates
beyond the confines of the orthosteric ligand-binding pocket.
Prostanoid receptor
From the same research laboratory as fluorescent H3R ligands
16–18 (Tomasch et al., 2012b; 2012c) was the report of a
fluorescent prostanoid EP3 receptor (EP3R) antagonist (26)
(Tomasch et al., 2012a). Based on an ortho-substituted cin-
namic acid antagonist, a series of fluorescent conjugates
were synthesized containing different fluorophores, with
pyrylium-containing 26 showing the most promise as an
imaging tool. Although with approximately threefold
reduced affinity for the human EP3R compared with the
parent drug molecule, 26 maintained selectivity over the
EP1R, EP2, and EP4R subtypes. The authors then proceeded to
demonstrate that the EP3R receptor could be visualized using
26 in murine kidney and human brain tissue.
Vasopressin receptor
Loison et al. (2012) reported the first examples of selective,
fluorescent, non-peptidic ligands for the vasopressin V2 recep-
tor (V2R) based on a tetrahydro-1H-benzo[b]azepine antago-
nist. A series of conjugates containing different linker lengths
and fluorophores were synthesized, and from these, three
lead compounds (27–29) were identified. Interestingly,
although compounds 27–29 displayed a slight decrease in
affinity for the human V2R compared with the parent ligand,
these fluorescent conjugates were comparatively more selec-
tive for the V2R over the V1AR and oxytocin receptor. Cyanine
probe 28 and terbium-containing 29 (the nature of the linker
housed within the fluorophore is not represented, it has been
presumed this is the commercially available Lumi4-Tb-NHS
ester as stated in the publication) were then used to develop
an acceptor/donor V2R TR-FRET-based assay and utilized as a
tool to study V2R-V1AR dimerization in association with a
previously reported V1AR probe (Albizu et al., 2010).
Other fluorescent Class A GPCR ligands
In addition to fluorescent probes specifically designed to
target Class A GPCRs there have been recent reports of fluo-
rescent ligands for alternative receptors, but which one would
predict might also bind to Class A GPCRs. There are two
recent reports (Céspedes-Guirao et al., 2011; Jose et al., 2011)
outlining the synthesis and application of fluorescent
oestradiol-based probes (30) and (31) to target the nuclear
hormone oestrogen receptor (ER). Although the ER is not
classified as a GPCR, the other type of oestrogen receptor,
GPER (or GPR30), is classified as a Class A GPCR. Oestradiol is
a high-affinity ligand for both the ER and the GPER; there-
fore, oestradiol-based conjugates developed for the ER may
well be useful tools for studying GPER. In addition to the
GPCR families covered in this review, there continues to be
an interest in developing small-molecule fluorescent probes
for the dopamine receptor, another Class A GPCR, although
there have been no new reports published of novel ligands
since the preceding review articles (Kuder and Kiec´-
Kononowicz, 2008; Böhme and Beck-Sickinger, 2009).
Another Class A GPCR for which developing fluorescent
ligands is an exciting prospect is the opioid receptor, but
since the last GPCR fluorescent ligand reviews, there have
only been reports of peptide, or peptide-based ligands conju-
gated to a fluorophore (e.g. Josan et al., 2009), and is therefore
outside the scope of this review article. In addition to the
novel fluorescent conjugates reported via peer-reviewed pub-
lications that have been discussed in this review, there are a
growing number of fluorescent conjugates available commer-
cially, with and without the chemical structure disclosed. In
an excellent example that showcased the power of using
several commercially available fluorescent probes that emit at
different wavelengths, Daly et al. (2010) investigated the dis-
tribution of adrenoceptors and ‘cannabinoid-like’ receptors
in different cell types.
Conclusion
While fluorescent ligands boast over a 30-year pedigree in
their application for the study of cellular receptors, it remains
clear from all reported research activity within the past
decade (including the more recent developments highlighted
in this review) that their usage is indeed escalating. This has
been accompanied by advances in microscopy and live cell
imaging, which have made it possible to visualize and
measure the receptor life cycle. One such receptor family class
that has benefitted immensely from fluorescent ligand devel-
opment is GPCRs. The fluorescent conjugates described
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within this review have helped to crystallize many of the key
factors for consideration when appending a fluorophore to a
relatively small orthosteric drug molecule. The linker that
connects the fluorescent moiety to the drug of interest must
be attached to a position that is relatively insensitive to
structural modification and that can potentially tolerate
bulky substituents. In order to attenuate non-specific binding
of the fluorescent-drug conjugate, one must also be mindful
of the final physicochemical properties of the molecule.
Finally, when using the generated probes for cellular-based
imaging studies or certain types of assay, it has become clearer
that judicious choice of the correct fluorophore is also of
paramount importance. The work summarized in this and
previous reviews unequivocally substantiates that if all these
considerations are taken into account, the resulting fluores-
cent conjugates are extremely powerful pharmacological
tools that can be utilized in numerous cutting-edge assay
formats. An interesting road lies ahead for all researchers in
this area in attempting to rationalize the ligand–receptor
interactions of fluorescent conjugates beyond the confines of
the orthosteric ligand-binding pocket. In so-doing though,
this will undoubtedly help cement the use of these fluores-
cent reagents as versatile and extremely useful tools for
modern-day molecular pharmacology and drug discovery.
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